A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?
Luis Ramos-RupertoEduardo García-PérezD Hernández-MaraverA Kerguelén-FuentesA Viejo-LlorenteÁ Robles-MarhuendaC Busca-ArenzanaPublished in: SN comprehensive clinical medicine (2021)
COVID-19 has rarely been associated with immune-mediated phenomena such as autoimmune haemolytic anaemia (AIHA). Both cold hemolysis with cold agglutinin detection and warm haemolysis have been described with variable prognoses. Current treatment regimens are based on experience with other case series and case reports, which still represent a clinical challenge. Corticosteroids, red cell transfusions and rituximab have been successfully employed. We present 3 cases of AIHA in the context of COVID-19 disease, the first case successfully treated with plasma exchange and long-term follow-up of the 3 cases showing complete remission of anaemia.
Keyphrases
- coronavirus disease
- sars cov
- iron deficiency
- multiple sclerosis
- respiratory syndrome coronavirus
- single cell
- diffuse large b cell lymphoma
- case report
- cell therapy
- stem cells
- disease activity
- mesenchymal stem cells
- systemic lupus erythematosus
- drug induced
- loop mediated isothermal amplification
- hodgkin lymphoma
- chronic lymphocytic leukemia
- real time pcr
- replacement therapy
- quantum dots
- bone marrow
- red blood cell
- sensitive detection